Sucampo
Sucampo Pharmaceuticals, a US biopharma firm specialising in “prostones”, naturally-occurring compounds made from the transformation of fatty acids, has appointed Peter Greenleaf as CEO.
Greenleaf, 43, has worked in biopharmaceutical development for more than 20 years. He heads Histogenics, a regenerative medicine company, and was previously president of MedImmune, the global biologics arm of AstraZeneca. He has also worked for Centocor and Boehringer Mannheim.
Greenleaf replaces the company’s co-founder, Ryuji Ueno, as CEO. Ueno will also step down as Chief Scientific Officer on March 31.
Sucampo has additionally named Dan Getman as Chairman of the Board. Getman, who is currently Chairman of the company’s Science and Technology Committee, will take on the role on March 3.